Balyasny Asset Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Balyasny Asset Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,562	Closed	-$149K	–	3420
2024 Q4	$149K	Buy	+15,562	New	+$81.2K	﹤0.01%	2567
2024 Q2	–	Sell	-56,837	Closed	-$181K	–	3227
2024 Q1	$181K	Buy	+56,837	New	+$190K	﹤0.01%	2431
2023 Q2	–	Sell	-15,592	Closed	-$48K	–	2919
2023 Q1	$48K	Sell	15,592 -11,059	-41%	-$66.3K	﹤0.01%	2392
2022 Q4	$141K	Buy	+26,651	New	+$122K	﹤0.01%	2201
2021 Q3	–	Sell	-80,202	Closed	-$804K	–	2518
2021 Q2	$804K	Buy	+80,202	New	+$718K	﹤0.01%	1382

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Balyasny Asset Management's PSTX Position: Q1 2025 in Review

Balyasny Asset Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 15,562 shares — an estimated $149K sold.

Balyasny Asset Management first reported a position in PSTX in Q2 2021 and held it in 5 quarters. The position peaked at $804K in Q2 2021. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Balyasny Asset Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Balyasny Asset Management sold 15,562 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $149K.
Balyasny Asset Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Balyasny Asset Management's Poseida Therapeutics, Inc. Common Stock position peaked at $804K in Q2 2021.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.